المؤلفون: E. V. Loshkova, I. V. Doroshenko, T. S. Lyulka, Y. S. Rafikov, V. A. Zhelev, S. P. Ermolenko, E. V. Mikhalev, I. R. Grishkevich, N. E. Melnikov, A. L. Solnyshko, A. A. Bogunetsky, E. I. Kondratieva, A. I. Khavkin, N. D. Odinaeva, E. I. Makarevich, Е. В. Лошкова, И. В. Дорошенко, Т. С. Люлька, Ю. С. Рафикова, В. А. Желев, С. П. Ермоленко, Е. В. Михалев, И. Р. Гришкевич, Н. Е. Мельников, А. Л. Солнышко, А. А. Богунецкий, Е. И. Кондратьева, А. И. Хавкин, Н. Дж. Одинаева, Е. И. Макаревич

المصدر: Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics); Том 68, № 6 (2023); 85-93 ; Российский вестник перинатологии и педиатрии; Том 68, № 6 (2023); 85-93 ; 2500-2228 ; 1027-4065

مصطلحات موضوعية: негативные последствия для плода, new psychoactive substances, “bath salts”, pregnancy, prematurity, bone fractures, negative consequences for the fetus, новые психоактивные вещества, «соли», беременность, недоношенность, переломы костей

وصف الملف: application/pdf

Relation: https://www.ped-perinatology.ru/jour/article/view/1910/1439; Palamar J.J., Su M.K., Hoffman R.S. Characteristics of novel psychoactive substance exposures reported to New York City Poison Center, 2011–2014. Am J Drug Alcohol Abuse 2016; 42(1): 39–47. DOI:10.3109/00952990.2015.1106551; Wood K.E. Exposure to bath salts and synthetic tetrahydrocannabinol from 2009 to 2012 in the United States. J Pediatr 2013; 163(1): 213–216. DOI:10.1016/j.jpeds.2012.12.056; Ebrahim S.H., Gfroerer J. Pregnancy-related substance use in the United States during 1996–1998. Obstet Gynecol 2003; 101(2): 374–379. DOI:10.1016/s0029–7844(02)02588–7; Greenfield S.F., Manwani S.G., Nargiso J.E. Epidemiology of substance use disorders in women. Obstet Gynecol Clin North Am 2003; 30(3): 413–446. DOI:10.1016/s0889–8545(03)00072-x; Chang J.C., Holland C.L., Tarr J.A., Rubio D., Rodriguez K.L., Kraemer K.L. et al. Perinatal Illicit Drug and Marijuana Use. Am J Health Promot 2017; 31(1): 35–42. DOI:10.4278/ajhp.141215-QUAL-625; Gómez-Ruiz L.M., Marchei E., Rotolo M.C., Brunetti P., Mannocchi G., Acosta-López A. et al. Prevalence of Licit and Illicit Drugs Use during Pregnancy in Mexican Women. Pharmaceuticals (Basel) 2022; 15(3): 382. DOI:10.3390/ph15030382; Gunn J.K., Rosales C.B., Center K.E., Nuñez A., Gibson S.J., Christ C., Ehiri J.E. Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. BMJ Open. 2016; 6(4): e009986. DOI:10.1136/bmjopen-2015–009986; Marchand G., Masoud A.T., Govindan M., Ware K., King A., Ruther S. et al. Birth Outcomes of Neonates Exposed to Marijuana in Utero: A Systematic Review and Meta-analysis. JAMA Netw Open 2022; 5(1): e2145653. DOI:10.1001/jamanetworkopen.2021.45653; Reece A.S., Hulse G.K. Epidemiological overview of multidimensional chromosomal and genome toxicity of cannabis exposure in congenital anomalies and cancer development. Sci Rep 2021; 11(1): 13892. DOI:10.1038/s41598–021–93411–5; Kalix P. A constituent of khat leaves with amphetamine-like releasing properties. Eur J Pharmacol 1980; 68(2): 213–215. DOI:10.1016/0014–2999(80)90326-x; Hadlock G.C., Webb K.M., McFadden L.M., Chu P.W., Ellis J.D., Allen S.C. et al. 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 2011; 339(2): 530–536. DOI:10.1124/jpet.111.184119; Pehek E.A., Schechter M.D., Yamamoto B.K. Effects of cathinone and amphetamine on the neurochemistry of dopamine in vivo. Neuropharmacology 1990; 29(12): 1171–1176. DOI:10.1016/0028–3908(90)90041-o; den Hollander B., Sundström M., Pelander A., Ojanperä I., Mervaala E., Korpi E.R., Kankuri E. Keto amphetamine toxicity-focus on the redox reactivity of the cathinone designer drug mephedrone. Toxicol Sci 2014; 141(1): 120–131. DOI:10.1093/toxsci/kfu108; López-Arnau R., Martínez-Clemente J., Rodrigo T., Pubill D., Camarasa J., Escubedo E. Neuronal changes and oxidative stress in adolescent rats after repeated exposure to mephedrone. Toxicol Appl Pharmacol 2015; 286(1): 27–35. DOI:10.1016/j.taap.2015.03.015; Buzhdygan T.P., Rodrigues C.R., McGary H.M., Khan J.A., Andrews A.M., Rawls S.M., Ramirez S.H. The psychoactive drug of abuse mephedrone differentially disrupts blood-brain barrier properties. J Neuroinflammation 2021; 18(1): 63. DOI:10.1186/s12974–021–02116-z; Martínez-Clemente J., López-Arnau R., Abad S., Pubill D., Escubedo E., Camarasa J. Dose and time-dependent selective neurotoxicity induced by mephedrone in mice. PLoS One 2014; 9(6): e99002. DOI:10.1371/journal.pone.0099002; Tarkowski P., Jankowski K., Budzyńska B., Biała G., Boguszewska-Czubara A. Potential pro-oxidative effects of single dose of mephedrone in vital organs of mice. Pharmacol Rep 2018; 70(6): 1097–1104. DOI:10.1016/j.pharep.2018.05.010; Naseri G., Fazel A., Golalipour M.J., Haghir H., Sadeghian H., Mojarrad M. et al. Exposure to mephedrone during gestation increases the risk of stillbirth and induces hippocampal neurotoxicity in mice offspring. Neurotoxicol Teratol 2018; 67: 10–17. DOI:10.1016/j.ntt.2018.03.001; Adám A., Gerecsei L.I., Lepesi N., Csillag A. Apoptotic effects of the ‘designer drug’ methylenedioxypyrovalerone (MDPV) on the neonatal mouse brain. Neurotoxicology 2014; 44: 231–236. DOI:10.1016/j.neuro.2014.07.004; Yang Z., Klionsky D.J. Mammalian autophagy: core molecular machinery and signaling regulation. Curr Opin Cell Biol 2010; 22(2): 124–131. DOI:10.1016/j.ceb.2009.11.014; Yang Z.J., Chee C.E., Huang S., Sinicrope F. Autophagy modulation for cancer therapy. Cancer Biol Ther 2011; 11(2): 169–176. DOI:10.4161/cbt.11.2.14663; Valente M.J., Amaral C., Correia-da-Silva G., Duarte J.A., Bastos M.L., Carvalho F. et al. Methylone and MDPV activate autophagy in human dopaminergic SH-SY5Y cells: a new insight into the context of β-keto amphetamines-related neurotoxicity. Arch Toxicol 2017; 91(11): 3663–3676. DOI:10.1007/s00204–017–1984-z; Matsunaga T., Morikawa Y., Kamata K., Shibata A., Miyazono H., Sasajima Y. et al. α-Pyrrolidinononanophenone provokes apoptosis of neuronal cells through alterations in antioxidant properties. Toxicology 2017; 386: 93–102. DOI:10.1016/j.tox.2017.05.017; Siedlecka-Kroplewska K., Wrońska A., Stasiłojć G., Kmieć Z. The Designer Drug 3-Fluoromethcathinone Induces Oxidative Stress and Activates Autophagy in HT22 Neuronal Cells. Neurotox Res 2018; 34: 388–400. DOI:10.1007/S12640– 018–9898-Y; Angoa-Pérez M., Kane M.J., Francescutti D.M., Sykes K.E., Shah M.M., Mohammed A.M. et al. Mephedrone, an abused psychoactive component of ‘bath salts’ and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum. J Neurochem 2012; 120(6): 1097–1107. DOI:10.1111/j.1471–4159.2011.07632. x; Marusich J.A., Gay E.A., Stewart D.A., Blough B.E. Sex differences in inflammatory cytokine levels following synthetic cathinone self-administration in rats. Neurotoxicology 2022; 88: 65–78. DOI:10.1016/j.neuro.2021.11.002; Kim O.H., Jeon K.O., Jang E.Y. Alpha-pyrrolidinopentiothiophenone (α-PVT) activates the TLR-NF-κB-MAPK signaling pathway and proinflammatory cytokine production and induces behavioral sensitization in mice. Pharmacol Biochem Behav 2022; 221: 173484. DOI:10.1016/j.pbb.2022.173484; Pichini S., Rotolo M.C., García J., Girona N., Leal L., García-Algar O., Pacifici R. Neonatal withdrawal syndrome after chronic maternal consumption of 4-methylethcathinone. Forensic Sci Int 2014; 245: e33–е35. DOI:10.1016/j.forsciint.2014.10.027; Adamowicz P., Hydzik P. Fetal death associated with the use of 3,4-MDPHP and α-PHP. Clin Toxicol (Phila) 2019; 57(2): 112–116. DOI:10.1080/15563650.2018.1502443; Grapp M., Kaufmann C., Ebbecke M. Toxicological investigation of forensic cases related to the designer drug 3,4-methylenedioxypyrovalerone (MDPV): Detection, quantification and studies on human metabolism by GC-MS. Forensic Sci Int 2017; 273: 1–9. DOI:10.1016/j.forsciint.2017.01.021; https://www.ped-perinatology.ru/jour/article/view/1910

الاتاحة: https://www.ped-perinatology.ru/jour/article/view/1910
https://doi.org/10.21508/1027-4065-68-6-85-93